Goldman Sachs
JSPR icon

Goldman Sachs’s Jasper Therapeutics JSPR Stock Holding History

Goldman Sachs’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,746,492
Closed -$3.2M – 6764
2025
Q4 		$3.2M Buy
1,746,492
+1,719,602
+6,395% +$3.45M ﹤0.01% 4166
2025
Q3 		$64K Sell
26,890
-222,903
-89% -$676K ﹤0.01% 6143
2025
Q2 		$1.39M Buy
249,793
+16,035
+7% +$78.9K ﹤0.01% 4461
2025
Q1 		$1.01M Buy
233,758
+23,453
+11% +$156K ﹤0.01% 4685
2024
Q4 		$4.5M Buy
210,305
+154,540
+277% +$3.22M ﹤0.01% 3550
2024
Q3 		$1.05M Buy
55,765
+19,564
+54% +$390K ﹤0.01% 4605
2024
Q2 		$822K Buy
+36,201
New +$868K ﹤0.01% 4530
2023
Q2 		– Sell
-3,104
Closed -$56.2K – 5916
2023
Q1 		$56.2K Buy
+3,104
New +$57.4K ﹤0.01% 5535
2022
Q3 		– Sell
-1,027
Closed -$20K – 6416
2022
Q2 		$20K Sell
1,027
-18
-2% -$513 ﹤0.01% 6170
2022
Q1 		$37K Sell
1,045
-730
-41% -$32.9K ﹤0.01% 6318
2021
Q4 		$139K Buy
+1,775
New +$166K ﹤0.01% 6025
2021
Q3 		– Sell
-28,397
Closed -$2.82M – 6372
2021
Q2 		$2.82M Hold
28,397
– – ﹤0.01% 3887
2021
Q1 		$2.81M Sell
28,397
-6,403
-18% -$651K ﹤0.01% 3647
2020
Q4 		$3.48M Sell
34,800
-17,126
-33% -$1.7M ﹤0.01% 3291
2020
Q3 		$5.15M Buy
+51,926
New +$5.19M ﹤0.01% 2868

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Goldman Sachs's JSPR Position: Q1 2026 in Review

Goldman Sachs sold out of Jasper Therapeutics (JSPR) in Q1 2026, closing a stake of 1,746,492 shares — an estimated $3.2M sold.

Goldman Sachs first reported a position in JSPR in Q3 2020 and held it in 15 quarters. The position peaked at $5.15M in Q3 2020. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Goldman Sachs reported no remaining Jasper Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 1,746,492 Jasper Therapeutics shares in Q1 2026, an estimated $3.2M.
  • Goldman Sachs first reported a position in Jasper Therapeutics in Q3 2020 and held it in 15 quarters.
  • Goldman Sachs's Jasper Therapeutics position peaked at $5.15M in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.